Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Prostate Cancer
•
Medical Oncology
How would you choose between Leuprorelin (GnRH Agonist) vs relugolix (GnRH antagonist) in patients with intermediate or high-risk prostate cancer who received definitive radiation.
Related Questions
How do you manage PSA progression while a patient is on xofigo or pluvicto?
What are your top takeaways in GU Cancers from ESMO 2024?
Are there any contraindications to Pluvicto therapy you personally use, given that there are none directly provided by the manufacturer?
What are your top takeaways from ASCO GU 2025?
Given results of the RADICALS trials, is LT-ADT standard of care for salvage prostate RT?
How would you sequence PARPi vs pembrolizumab for a patient who has progressed on ARPI to mCRPC that has somatic PALB2 mutation and MSI-H?
Would you use olaparib after progression on an ARPI for a patient with somatic PALB2 mutated mCRPC?
When do you start ADT for a patient with a new diagnosis of node positive prostate cancer receiving radiation?
How would you approach de novo metastatic castrate sensitive prostate cancer with extensive locoregional spread causing rectal compression, retroperitoneal lymphadenopathy, and PSA >3000 but no visceral or bone metastases?
How do you follow/manage patients with metastatic prostate cancer with undetectable PSA and castration-sensitive but active disease on PSMA PET?
